Korean J Dermatol.  2018 Nov;56(9):548-551.

A Case of Paradoxical Flare of Pustular Psoriasis after Ustekinumab Therapy

Affiliations
  • 1Department of Dermatology, School of Medicine, Kyung Hee University, Seoul, Korea. mdfamily@hanmail.net

Abstract

Biologics are the most advanced treatment for psoriasis. Ustekinumab, one of the biologics for psoriasis, is a human monoclonal antibody that binds to the p40 subunit of interleukin-12 and interleukin-23. A 41-year-old woman with a 17-year history of plaque psoriasis and psoriatic arthritis presented with worsening lesions. The patient had previously been treated with a number of topical and systemic medications and narrow band ultraviolet B. However, none of the treatments consistently controlled her disease. Thus, treatment with ustekinumab 45 mg via subcutaneous injection was initiated. Approximately 7 days after the first treatment, she experienced a flare with generalized pustules in her whole body. The condition was controlled with systemic steroid treatment. The patient was subsequently treated with adalimumab, and improvement in her plaque and pustular lesions was noted. Herein, we report a case of psoriasis that flared up after ustekinumab therapy, which was accompanied by a morphological change from plaque to pustular lesions.

Keyword

Adalimumab; Biological products; Psoriasis; Ustekinumab

MeSH Terms

Adalimumab
Adult
Arthritis, Psoriatic
Biological Products
Female
Glycogen Storage Disease Type VI
Humans
Injections, Subcutaneous
Interleukin-12
Interleukin-23
Psoriasis*
Ustekinumab*
Adalimumab
Biological Products
Interleukin-12
Interleukin-23
Ustekinumab
Full Text Links
  • KJD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr